Posts by: Alice Melão

Alice Melão

October 17, 2018

Entinostat-Keytruda Combo Shows Promise in Certain NSCLC Patients who Received Prior Immune Checkpoint Therapies

News

A combination of Syndax‘s entinostat and Keytruda (pembrolizumab) has shown clinically meaningful activity in patients with non-small cell lung cancer (NSCLC) who received prior chemotherapy and a PD-1 or PD-L1 inhibitor, Phase 3 trial ... Read more

October 12, 2018

Bayer Begins Phase 1 Trial of BAY 1905254 Immunotherapy for Advanced Solid Cancers

News

Bayer has initiated patient dosing in a Phase 1 trial assessing the investigational immunotherapy BAY 1905254 in advanced solid tumors. The study is currently recruiting in Texas and plans to recruit in ... Read more

September 25, 2018September 25, 2018

FDA Grants Priority Review to Keytruda as First-line Therapy for Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) has agreed to review Merck‘s application seeking the extension of Keytruda (pembrolizumab) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC). The ... Read more

August 30, 2018August 30, 2018

Mutations in MUC16 Gene May Help Define Immunotherapy Strategies for Gastric Cancer, Study Suggests

News

Mutations in the MUC16 gene may help predict disease outcome and provide treatment guidance for gastric cancer patients, researchers suggest. These mutations are also linked to a higher mutational burden, which ... Read more

August 28, 2018August 28, 2018

New Scoring System May Help Predict Patient Response to Checkpoint Inhibitors, Study Reports

News

A newly developed scoring system could help identify melanoma patients who may benefit the most from treatment with a type of immunotherapy known as a checkpoint inhibitor, a study finds. The ... Read more

August 23, 2018August 23, 2018

Genprex, MD Anderson to Explore Oncoprex-Immunotherapies Combo in Broad Array of Cancers

News

Genprex has entered a sponsored research agreement with The University of Texas MD Anderson Cancer Center to further explore its investigational therapeutic candidate Oncoprex. The company will provide $2 million ... Read more

August 7, 2018August 7, 2018

BioLineRx Initiates Phase 1/2a Trial Testing AGI-134 in Metastatic Solid Tumors

News

A Phase 1/2a clinical trial is seeking patients with metastatic solid tumors who are unfit for surgery to participate in a study of BioLineRx‘s immunotherapy AGI-134. The trial (NCT03593226) is expected to enroll ... Read more

August 3, 2018August 3, 2018

Advaxis to Open Phase 1 Trial of ADXS-503, Potential Immunotherapy for Metastatic NSCLC

News

ADXS-503, an investigational treatment for non-small cell lung cancer that targets mutations in tumor driver genes, will soon move into a first clinical trial in patients, its developer, Advaxis, announced. The Phase ... Read more

August 1, 2018

FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal Cancer

News

Celyad will soon begin clinical development of its immunotherapy CYAD-101 (CAR-T NKG2D) and evaluate its potential as a treatment for patients with colorectal cancer that cannot be surgically removed. The first-in-human ... Read more

July 27, 2018July 27, 2018

Vyriad Expands Phase 1 Trial to Test Voyager-V1 in Combination with Bavencio for Colorectal Cancer

News

Vyriad is expanding its ongoing Phase 1 clinical trial testing Voyager-V1, its lead virotherapy candidate, to include a combination study with PD-L1 inhibitor Bavencio (avelumab) for metastatic colorectal cancer patients. The ... Read more